Skip to main content
Fig. 4 | BMC Health Services Research

Fig. 4

From: Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity

Fig. 4

One-way sensitivity analysis: Tornado diagram indicates the percentage of change from mean ICER when each parameter is varied in its plausible range. Only the biosimilar infliximab (Ixifi®) + methotrexate result was selected for analysis. DAS: Disease Activity Score, M2R: transitional probability from moderate / low disease activity to remission, H2R: transitional probability from high disease activity to remission, bsIFXi: Biosimilar infliximab (Ixifi®)

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us